Table 1. Patient characteristics.
| Group | HIV+ART− | HIV+ART+ | EC | AI | HC |
|---|---|---|---|---|---|
| No of subjects | 30 | 20 | 14 | 12 | 31 |
| Age | 40 (33–47) | 48 (43–55) | 48 (41–54) | 34 (28–43) | 33 (31–40) |
| Gender | 57% M | 70% M | 80% M | 100% M | 68% M |
| CD4 count (cells/mm3) | 419 (302–552) | 700 (590–940) | 1110 (719–1399) | 575 (343–818) | N.A |
| CD4% | 21 (17–27) | 36 (30–42) | 43 (32–50) | N.A | N.A |
| CD4/CD8 | 0.38 (0.24–0.66) | 0.92 (0.81–1.34) | 1.26 (0.93–1.75) | 0.74 (0.26–1.05) | N.A |
| VL (copies/mL) | 31,000 (7,390–188,750) | <50 | <50 | 500,000 (100,579–1,530,000) | N.A |
| Time after estimated infection date | 3 (1–7) years | 16 (12–20) years | N.A | 27 (24–30) days | N.A |
| Years on treatment | Naïve | 14 (10–17) | Naïve | Naïve | N.A |
Median and IQR are shown for all values.
HIV+ART−: HIV-infected treatment naïve subjects; HIV+ART+: HIV-infected subjects on long-term (>6 yrs) treatment; EC: Elite controllers; AI: Subjects with acute HIV-infection; HC: Healthy controls; M: Male; VL: Viral load; N.A: Not Available.